The role of E-cadherin expression in the treatment of western undifferentiated early gastric cancer: Can a biological factor predict lymph node metastasis?

The use of endoscopic techniques to cure small sized, well differentiated early gastric cancer has been adopted worldwide. In the Eastern world, endoscopic resection is being increasingly utilized to treat small undifferentiated early gastric cancer according to the extended criteria proposed by the Japanese Gastric Cancer Associations. However, studies in the Western world reported in these tumors a rate of nodal metastasis ranging between 5% and 20%, that is higher of those observed in Eastern counterparts. A tool to predict the risk of nodal dissemination would be of great use to guide treatment toward endoscopic resection. In our study, we propose E-cadherin expression as a biological factor to predict lymph node involvement. We retrospectively reviewed the E-cadherin (E-cad) expression profile of all histological specimens of undifferentiated early gastric cancer from two Oncologic Departments and compared it with several tumor characteristics. A total of 39 patients with early gastric cancer met the inclusion criteria, of which 16 (41%) pT1a, and 23 (58.9%) pT1b SM1. Thirty-two patients (82%) underwent subtotal gastrectomy, whereas total gastrectomy was performed in only seven cases (17.9%). Patients were divided into two groups: low E-cad expression (E-cad 0/1+, 10 patients) and high E-cad expression (E-cad 2+/3+, 29 patients) according to the immunohistochemical assay (ICH). On univariate analysis, we found an association between low E-cad expression and low grading tumor (p = 0.019), pure undifferentiated histotype (PU-type) (p = 0.014), and lymph node involvement (N+) (p < 0.001). The association between low E-cad expression and lymph node metastasis was confirmed by multivariate analysis (OR = 14.5, 95% CI 3.46-60.76, p < 0.001). The loss of expression of E-cad may be a simple biological factor to predict lymph nodes metastasis in patients with undifferentiated early gastric cancer. Additional larger prospective studies are necessary to confirm these findings.

Introduction

Early gastric cancer (EGC) is defined as a gastric cancer (GC) confined to the mucosa (pT1a) or the submucosa (pT1b) irrespective of lymph node metastasis (LNM). It bears a more favorable prognosis after conventional gastrectomy with nodal dissection compared to advanced gastric cancer cases [1].

For small EGC, endoscopic treatment such as mucosal resection (EMR) and submucosal dissection (ESD) has been widely adopted as an alternative to conventional surgery, because it preserves gastric function and consequently leads to an improved quality of life [2,3]. Endoscopic resection of small EGC is a standard therapy in Asia (Japan, China, and Korea) and is being increasingly utilized in the USA and Europe.

The Japanese Gastric Cancer Associations guidelines [4] proposed two different sets of endoscopic resections: standard and expanded. Both procedures are considered curative when all of the following conditions are met: en-bloc resection, negative horizontal margin (HM0), negative vertical margin (VM0), and absence of lympho-vascular infiltration.

Recently, the National Comprehensive Cancer Network (NCCN) [5] endorsed the Japanese Gastric Cancer guidelines and proposed EMR/ESD for small-sized (≤ 2 cm) well and moderately well differentiated EGC. However, these organ-sparing approaches do not involve lymph node dissection. The incidence of lymph node metastasis (LNM) in EGC ranges from 5% to 20% according to the tumor stage, size, grade of differentiation, and geographic area [2-3]. This significant variability of LNM between geographic areas could be secondary to the different biological behavior of these tumors.

The rate of nodal metastasis for tumor confined to the mucosa (pT1a) is significantly higher in Western countries [6] (5–20%) than in Eastern ones (not exceeding 5%) [7]. According to the USA national SEER database, LNM for low-grade T1a tumors was present in 1.7%, 4.1%, 4.5%, and 20% for 0–2cm, 2–3cm, 3–4cm, and ≥ 4 cm tumor size, respectively [6].

On the other hand, there are only case reports that describe nodal involvement in small undifferentiated Eastern EGC [8,9].

Thus, in order to safely perform conservative endoscopic resection in western undifferentiated EGC, the risk of concurrent nodal metastasis should be accurately investigated. We propose the use of E-cadherin expression as a possible early biological factor to predict lymph node involvement and to guide the selection of less invasive treatment modalities.

Materials and methods

Ethics statement

Patients were not required to give consent for this study, due to the retrospective nature of the study. All analyzed data was anonymized without identifiers. The study was reviewed and approved by the Institutional Review Board and by the Ethics Committee of the General Surgery Department of Catania.

Study design

We retrospectively reviewed the medical records of all the patients who were treated for gastric cancer at two large referral institutions (the Department of Surgery of the University of Catania and the Department of Surgery of the Main Hospital of Lodi) between October 2015 and October 2019 All patients with undifferentiated pT1a or pT1b (SM1 < 500 μm from the muscularis mucosae) EGC were included in the study and their histological specimens were tested for E-cadherin expression profile. The primary endpoint was the evaluation of the prevalence of LNM and the correlation with the degree of E-cadherin expression. The overall surgical outcomes were also analyzed and reported. Preoperative assessment included a complete medical history, physical examination, endoscopic ultrasound (EUS) to measure the depth of invasion, and upper gastrointestinal endoscopy with biopsies. Abdominal and chest CT scans were performed to assess the presence of local infiltration to adjacent organs, regional and distant nodal disease and lung, liver and/or peritoneal metastases. The goal of surgical procedure was a complete resection (R0) of the tumor.

Distal sub-total gastrectomy was performed in cases of tumors located in the lower and middle third of the stomach, if a proximal margin of at least 5 cm was feasible to achieve. Lymphadenectomy involved the systematic removal of perigastric lymph node stations (n° 1–7), and those along the celiac axis (n° 9), hepatic artery (n° 8a), splenic artery (n° 11p/d), and hepatoduodenal ligament (n° 12a). Lymph nodes at the splenic hilum were removed by splenectomy only when macroscopically involved.

The American Society of Anesthesiologists (ASA) score was used to stratify patients according to their perioperative risk. Tumor specimens were classified according to the Macroscopic Classification of the Japanese Gastric Cancer Association [4].

Immunohistochemistry (IHC)

A representative paraffin block was obtained from each case. Immunohistochemistry (IHC) examination was performed using an automatic immune-stainer (DAKO OMNIS). Subsequently, the slides were incubated for one hour with the corresponding monoclonal antibody (clone 36B5). Each immunohistochemical staining was evaluated through a photomicroscope (Olympus®). Image acquisition was performed by Nano Zoomer-XR C12000 series (Hamamatsu Photonics®). The E-cadherin (E-cad) expression profile was stratified according to the grading system described by Chu et al. [10]:

Absent (0): staining in fewer than 10% of tumor cells;

Low (1+): weak staining in only 10%-50% of tumor cells;

Low-intermediate (2+): moderate staining in 50%-75% of tumor cells;

High (3+): strong staining of more than 75% of tumor cells.

Statistical analysis

Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) version 20.0. Data were represented as absolute frequency. For the univariate analysis, Mann-Whitney U tests were used. A p-value <0.05 was considered significant with confidence intervals (CI) of 95%. For the multivariate analysis, we used Cox-logistic regression analysis.

Results

A total of 39 patients with early gastric cancer met the inclusion criteria, of which 16 (41%) pT1a, and 23 (58.9%) pT1b SM1. Thirty-two (82%) patients underwent subtotal gastrectomy, whereas total gastrectomy was performed in only seven cases (17.9%). Patient’s characteristics are summarized in Table 1. The mean age was 62.7 years (± 9.2) with female predominance (59%).

Table 1

Patient’s characteristics.

Patients	n/tot al (%)
Sex
Male	16/39 (41%)
Female	23/39 (59%)
Age (years)	62.7± 9.2 (range 45–75)
Gastrectomy
Subtotal	32/39 (82%)
Total	7/39 (18%)
ASA score
1	1/39 (2.6%)
2	11/39 (28.2%)
3	25/39 (64.1%)
4	2/39 (5.1%)
Macroscopic Type
Type-0- I	6/39 (15.4%)
Type-0-IIa	13/39 (33.3%)
Type-0- IIb	4/39 (10.2%)
Type-0-IIc	4/39 (10.2%)
Type-0- III	12/39 (30.8%)
Histological type
MU-Type	17/39 (43.6%)
PU-Type	22/39 (56.4%)
SRC	16/22 (72.7%)
Poor	5/22 (22.7%)
Muc	1/22 (4.5%)
pT Stage
pT1a	16/39 (41%)
pT1b (SM1)	23/39 (60%)
Grading
G1	10/39 (25.6%)
G2	18/39 (46.1%)
G3	11/39 (28.2%)
Ulcerative finding
UL (+)	18/39 (46.1%)
UL (-)	21/39 (53.8%)
pN
pN0	31/39 (79.5%)
pN1	8/39 (20.5%)

MU = mixed undifferentiated

PU = pure undifferentiated

SRC = signet-ring cell carcinoma

Poor = poorly solid adenocarcinoma

Muc = mucinous tumor

EGC was classified according to the Macroscopic Classification of the Japanese Gastric Cancer Association [4]: the majority of tumors were Type-0-IIa (33.3%) (superficial elevated) or Type 0-III (30.8%) (excavated). Six cases were Type-0-I (15.4%) (protruding), four were Type-0-IIb (10.2%) (superficial flat) and four Type-0-IIc (10.2%) (superficial depressed). Ulcerative findings (UL +) were present in 21/39 patients (53.8%).

Undifferentiated EGC included pure undifferentiated (PU-type; 56.4%) and predominantly or mixed undifferentiated cases (MU-type; 43.6%). Among PU-type tumors, there were 16 signet-ring cell carcinomas (SRC; 72.7%), five poorly solid or non-cohesive differentiated adenocarcinomas (poor; 22.7%) and one mucinous tumor (muc; 4.5%).

All patients underwent D2 lymphadenectomy and the mean number of lymph nodes retrieved was 15.47 (range 4–23). According to the 8th AJCC nodal involvement classification [11], our series included 31 (79.5%) pN0 cases (no regional lymph node metastasis) and eight (20.5%) pN1 cases (metastasis in one or two regional lymph nodes).

We analyzed the relationship between E-cad expression and some clinic-pathological features: histotype, depth of invasion, grading, tumor size and N status. All cases enrolled in our study were classified into two groups: low E-cadherin expression (E-cad 0/1+) and high E-cadherin expression (E-cad 2+/3+) (S1 Fig). On univariate analysis (Table 2), we found an association between low E-cadherin expression and low tumor grading (p = 0.019), pure undifferentiated histotype (PU-type) (p = 0.014) and lymph node involvement (N+) (p < 0.001). The association between low E-cadherin expression and lymph node metastasis (LNM) was confirmed by multivariate analysis (OR = 14.5, 95% CI 3.46–60.76, p < 0.001) (Table 3).

Table 2

Univariate analysis between low E-cadherin expression (E-cad 0 / +1) and high E-cadherin expression (E-cad +2 / +3).

	N° Positivity to E- cad 0/1+	N° Positivity to E-cad 2+/3+	Mann-Whitney U-Test (p)
Macroscopic Type			p = 0.144
Type-0- I	2	4
Type-0-IIa	3	10
Type-0- IIb	1	3
Type-0-IIc	0	4
Type-0- III	4	8
Histotype
			p = 0.014
MU-Type	1	16
PU-Type	9	13
Depth of invasion			p = 0.122
pT1a	2	14
pT1b sm1	8	15
Grading			p = 0.019
G1	1	9
G2	3	15
G3	6	5
Size			p = 0.415
< 1 cm	1	6
≥ 1 to ≤ 2 cm	3	12
>2 cm	6	11
N Status			p < 0.001
N0	2	29
N+	8	0

MU = mixed undifferentiated

PU = pure undifferentiated

Table 3

Multivariate analysis between low E-cadherin expression (E-cad 0 / +1) and high E-cadherin expression (E-cad +2 / +3).

	N° Positivity to E- cad 0/+1	N° Positivity to E-cad +2/+3	OR	(95% CI)	p
N Status			14.5	3.46–60.76	p < 0.001
N0	2	29
N+	8	0

Discussion

Gastric cancer (GC) incidence has decreased in Western countries due to the diffusion of eradication therapy for H. Pylori and the improvement in food preservation methods. However, GC is still the fifth solid cancer for frequency and the third cause of cancer-related death (over 934,000 new cases and 720,000 deaths per year) worldwide [12]. Early gastric cancer (EGC) is generally associated with a better prognosis, but nodal involvement has to be considered. Gastric cancer is classified in two different groups: differentiated and undifferentiated type. The former includes papillary adenocarcinoma (pap) and well and moderately differentiated tubular adenocarcinoma (tub1, tub2); the latter includes poorly-differentiated tubular adenocarcinoma, poorly differentiated adenocarcinoma, solid and non-solid type (por1, por2), signet-ring cell carcinoma (sig) and mucinous adenocarcinoma (muc) [13]. The risk of lymph node involvement is significantly higher for undifferentiated rather than differentiated tumors. Therefore, some cases of EGC may be characterized by unfavorable histological type, low degree of differentiation and high metastatic potential.

In order to obtain a more tailored treatment plan, an accurate research of early biological factors to predict lymph node metastasis is needed. Several markers have been studied, among which tumor size, depth of invasion, macroscopic and histological type are widely considered as risk factors for nodal involvement [14,15].

The metastatic capacity of cancer cells originates from the acquired ability to lose normal adhesion with adjacent structures (homing) and to spread through the lymphatic system or bloodstream with possible distant organ invasion. During the epithelial–mesenchymal transition (EMT), the loss of intercellular adhesions is likely to be the first step toward the metastatic phase. E-cadherin protein (endothelium calcium-dependent adhesion protein) plays a leading role in this process. It is a class of type 1 trans-membrane proteins that links catenins to form an E-cadherin/catenin complex which is linked to the actin cytoskeleton [16].

The use of E-cadherin (E-cad) expression as a molecular marker was analyzed in several studies leading to interesting but not definitive results.

In a retrospective study, Shun et al. [17] demonstrated a correlation between the loss of E-cad and the histological type, with abnormal expression being more frequent in diffuse-type tumors compared to intestinal-type (p < 0.0005). The authors also reported a correlation between abnormal expression of E-cad and a higher frequency of lymph node metastasis (LNM) (p < 0.05). Cai et al [18], in a large study on 162 patients, reported that the loss of E-cad together with lymphatic invasion of the primary tumor represented an independent risk factor for LNM (p < 0.05). Additionally, in a recent meta-analysis the authors [19] found a statistical correlation between the E-cad expression and some clinical variables such as depth of invasion (p < 0.001), lymph node spread (p < 0.001) and distant metastasis (p < 0.001), leading to a poor 5-year overall survival (p < 0.001).

The loss of E-cad expression can be caused by several mechanisms [20-24]. The mutation or deletion of CDH1 (E-cadherin gene) can be found in some hereditary gastric cancers [25] but it is also common in familiar cases [26]. On the other hand, in sporadic GC, somatic mutation of CDH1 is extremely rare and is more frequent in the diffuse phenotype [27]. In many cases there are no structural mutations, but the loss of E-cad is due to epigenetic alterations such as promoter hypermethylation or activation of transcriptional repressors.

MicroRNAs (non-coding RNAs) modulate CDH1 through the regulation of its transcription factors (EZH2, ZEB1 and ZEB2). Rossi T et al. [28] investigated the impact of microRNAs on intestinal gastric cancer (IGCs) compared to normal tissues. They found a significant downregulation of miR-101, miR-26b and miR-200 in respectively 57.6%, 51.5%, and 51.5% of IGCs. Moreover, miR-200 expression seems to act as tumor suppressor, correlating with lower tumor grade. Twist, Snail and Slug are transcriptional repressors of CHD1, inhibiting the expression of genes containing E-boxes in the promoter regions. Chen et al. [29] revealed Snail expression in metastatic lymph nodes. When tumor cells transfer from metastatic lymph nodes to another lymph node, Snail expression seems to be generally over-expressed. We believe that the new concept of the Snail switch, which is the positive-to-negative conversion of the Snail status in metastatic lymph nodes, may explain the loss of E-cad in the primary tumor. According to our results, E-cad expression may be a simple biological factor to predict LNM in patients with undifferentiated EGC. However, our study is subjected to many limitations, the most important of which is the relatively small series of cases enrolled. Larger studies are needed to validate this theory.

Conclusion

Detection of E-cad on undifferentiated EGC could be a feasible method to predict which patients should undergo endoscopic resection and which ones should be submitted to surgery with extended lymphadenectomy.

The E-cadherin (E-cad) expression by immunohistochemical assays (ICH).

(PDF)

Click here for additional data file.

17 Mar 2020

PONE-D-20-01711

The role of E-cadherin expression in the treatment of western undifferentiated early gastric cancer: can a biological factor predict lymph node metastasis?

PLOS ONE

Dear Dr Piccolo,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands.

The association between low E-cad expression and lymph nodes metastasis is not new but of interest and study to confirmed this point is of interest. However, authors must refer to prevalence and not to incidence of nodal involvement. Moreover, a correlation of macroscopic aspect of early gastric cancer with E-cad expression could improve the study.

Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by May 01 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Valli De Re, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

The name of the colleague or the details of the professional service that edited your manuscript

A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

3. At this time, we ask that you please provide additional information in your Methods section about the specific methodology used to conduct the immunohistochemical analysis in your study.

4. Thank you for stating the following financial disclosure:

'No'

Please provide an amended Funding Statement that declares *all* the funding or sources of support received during this specific study (whether external or internal to your organization) as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now

Please state what role the funders took in the study.  If any authors received a salary from any of your funders, please state which authors and which funder. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

c. Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

5. Please include a caption for figure 1.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is an interesting paper on an important topic. How to help to predict the presence of lymph node involvement in early gastric cancer. however authors must refer to prevalence and not to incidence of nodal involvment . Another interesting data is to correlate macroscopic aspect of early gastric cancer and E-cad. Paper must be revisad by native english

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

4 Apr 2020

Journal Requirements:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

We consulted PLOSE ONE’s online submission guidelines and carefully revised the manuscript style to meet the journal requirements.

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar.

The manuscript was kindly copyedited by natural English speaker: Emanuele Lo Menzo M.D, PhD, FACS, Associate Professor of Surgery, Department of General Surgery, Division of Minimally Invasive and Metabolic Surgery, Cleveland Clinic Florida, Weston, FL, USA.

3. At this time, we ask that you please provide additional information in your Methods section about the specific methodology used to conduct the immunohistochemical analysis in your study.

Thank you, we provided additional information about the IHC methodology used for the study and included it in the Methods section of the manuscript.

4. Please provide an amended Funding Statement that declares *all* the funding or sources of support received during this specific study.

The authors received no specific funding for this work. We modified our cover letter.

5. Please include a caption for figure 1.

Figure 1 along with its caption was submitted as supporting information in the requested style and format.

Review Comments to the Author

Reviewer #1: This is an interesting paper on an important topic. How to help to predict the presence of lymph node involvement in early gastric cancer. however authors must refer to prevalence and not to incidence of nodal involvment . Another interesting data is to correlate macroscopic aspect of early gastric cancer and E-cad. Paper must be revisad by native English

Thank you for the suggestion; We recognize our mistake in referring to incidence instead of prevalence and corrected it in the manuscript. The correlation between macroscopic features of EGC and E-Cad expression has been included in the revised manuscript. Paper has been revised by a native English speaker.

Submitted filename: Response to reviewers.docx

Click here for additional data file.

15 Apr 2020

The role of E-cadherin expression in the treatment of western undifferentiated early gastric cancer: can a biological factor predict lymph node metastasis?

PONE-D-20-01711R1

Dear Dr. Piccolo,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Valli De Re, Ph.D.

Academic Editor

PLOS ONE

Reviewers' comments:

authors make changes according to the request.

17 Apr 2020

PONE-D-20-01711R1

The role of E-cadherin expression in the treatment of western undifferentiated early gastric cancer: can a biological factor predict lymph node metastasis?

Dear Dr. Piccolo:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Valli De Re

Academic Editor

PLOS ONE